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ABSTRACT
Cancer testis antigens (CTAs) represented a poorly
characterized group of proteins whose expression is
normally restricted to testis but are frequently up-
regulated in cancer cells. Here we show that one
CTA, Luzp4, is an mRNA export adaptor. It asso-
ciates with the TREX mRNA export complex sub-
unit Uap56 and harbours a Uap56 binding motif, con-
served in other mRNA export adaptors. Luzp4 binds
the principal mRNA export receptor Nxf1, enhances
its RNA binding activity and complements Alyref
knockdown in vivo. Whilst Luzp4 is up-regulated in a
range of tumours, it appears preferentially expressed
in melanoma cells where it is required for growth.
INTRODUCTION
The transport of mRNA from the nucleus to the cytoplasm
is an essential step in eukaryotic gene expression. It is sub-
ject to rigorous quality control to ensure that only fully pro-
cessed mature mRNA exits the nucleus (1). A major mRNA
export pathway used in human cells involves the multisub-
unit TREX complex which comprises the THO complex
and numerous additional subunits (2,3). TREX integrates
information from transcription (4), splicing (5) and 3′ end
processing (6,7) to mark mature mRNAs for export. TREX
assembly requires Alyref, the THO complex, and is driven
by the Uap56 RNA helicase (3,8). A number of TREX sub-
units including Alyref, Chtop and Uif harbour a specific
peptide motif (Uap56 binding motif, UBM) that allows di-
rect interaction with Uap56 or its paralogue, Ddx39 (9,10).
Nxf1 is the major metazoan mRNA export receptor
which functions as a heterodimer with Nxt1 (11). Free Nxf1
sequesters its own N-terminal RNA binding domain but
upon binding to TREX, the RNA binding domain of Nxf1
is exposed allowing direct interactions with the mRNA
(12,13). The key TREX subunits responsible for this con-
formational change in Nxf1 (to allow mRNA binding) are
Alyref, which binds the N-terminal region of Nxf1, and
Thoc5 or Chtop, either of which can bind the NTF2-like
(NTF2L) domain (aa 371-550) (10,13). A number of other
proteins that function in a manner similar to Alyref in bind-
ing Nxf1 have been identified, including Uif, various SR
proteins and U2af1 (9,14–16). These interactions probably
ensure that multiple Nxf1 molecules are recruited to a sin-
gle mRNA, ensuring efficient translocation of the mRNP
across the nuclear pore. Whilst Nxf1 is the major mRNA
export receptor, there exist several other Nxf genes in hu-
mans (17) including Nxf2. Notably, Nxf2 destabilizes Nxf1
mRNA in testis and neurons and thus Nxf2 may represent
the major mRNA export receptor in these tissues (18).
There is increasing evidence that various proteins in-
volved in mRNA export are dysregulated in cancer cells
(19). These proteins include eIF4E which is up-regulated
in ∼30% of cancer cells. eIF4E is required for the export
of specific transcripts via the CRM1 pathway and also re-
models the nuclear pore complex which promotes mRNA
export and oncogenic transformation (20). The TREX sub-
unit Thoc5 is the target of leukaemogenic tyrosine kinases
(21) and two other TREX subunits, Thoc1 (Hpr1) and
Alyref, are dysregulated in cancer cells (22–24). Further-
more, the correct packaging of mRNA by TREX is impor-
tant to prevent R-loop formation and in TREX mutants, in-
creased R-loop formation leads to genome instability (24).
The TREX-2 complex, which is implicated in the transfer
of mRNA from the nuclear interior to the nuclear pore
complex (25), has also been shown to be associated with
BRCA-2 and is implicated in maintaining genome stability
(26). Together these studies highlight the close link between
packaging/export of mRNA and genome stability/cancer.
One important class of proteins implicated in cancer are
the cancer testis antigens (CTAs), which are a diverse collec-
tion of proteins characterized by their largely restricted ex-
pression in testis in the normal situation and up-regulation
in one or more cancers. Many CTAs reside on the X-
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chromosome and a key element in their induction in can-
cer cells appears to be promoter demethylation (27). The
unique expression characteristics of CTAs means they rep-
resent a promising group of targets both as biomarkers and
therapeutic targets in the treatment of cancer. However, de-
spite the identification of a wide variety of CTAs, in general
the molecular functions of this class of proteins are poorly
characterized though Nxf2 is classified as a CTA (28). Here,
we show that the CTA Luzp4 is an mRNA export factor re-
quired for efficient growth of melanoma cells.
MATERIALS AND METHODS
Plasmids, antibodies and cell culture
Plasmids encoding CBP80-Myc, MS2-GFP, MS2-Alyref,
MS2-Nxf1, pLUCSALRRE6MS2, GST-Uap56, GB1-
Nxf1 and truncations are described previously (12) as
were FLAG-Nxf1-myc, FLAG-GFP, FLAG-Srsf1-myc,
GST-Nxf1:p15 (13). FLAG-Uap56-myc was generated
by subcloning the Uap56 open reading frame into p3X-
FLAG-Myc-CMV26 (Sigma). Luzp4 cDNA (NM 016383)
used for all constructs was purchased from Source Bio-
science (clone MGC:149218, IMAGE:40112435, locus
BC128134). All Luzp4 constructs (wild-type or mutant)
used for in vitro pulldowns and UV-crosslinking experi-
ments were expressed as 6-His tagged fusions from pET24b
(cloned NdeI/XhoI as PCR products). FLAG-Luzp4
and Luzp4-myc used in co-immunoprecipitation (Co-IP)
experiments were expressed from p3XFLAG-myc-CMV26
(cloned HindIII/EcoRI) and pcDNA3.1-myc-HisB
(cloned BamHI/XhoI), respectively. To make the FLAG-
Luzp4 stable cell line, 3XFLAG-Luzp4 was amplified
by PCR from p3XFLAG-Luzp4-myc (see above) and
cloned NotI/XhoI into a modified pcDNA5-FRT-TO-
His where the start codon of the N-terminal 6His tag
was destroyed by site-directed mutagenesis. The cell
line was generated as previously described (9). A vector
pEGFPN1-Luzp4 (XhoI/BamHI) was built to monitor
GFP-Luzp4 localisation in HeLa cells. This vector was
used as a template to generate the deletion mutant con-
structs pEGFPN1-Luzp4(N) (amino acids 119–313),
pEGFPN1-Luzp4( aa 22–40), pEGFPN1-Luzp4( aa
156–236), pEGFPN1-Luzp4( aa 156–178) by divergent
PCR. pEGFPN1-luzp4(C) was made by amplifying
Luzp4 region encoding aa 1–240 by PCR and cloning the
resulting PCR product into pEGFPN1 (XhoI/BamHI).
For MS2 mRNA export assays, Luzp4 was amplified by
PCR as an NheI/NotI product and cloned in pCINeo-MS2
(XbaI/NotI), described previously (9). Antibodies were
obtained from the following suppliers Thoc1 (Hpr1),
Nxf1 and Alyref (Abcam); Ars2 (Santa Cruz); Hnrnpa1
(Millipore); FLAG, Tubulin (Sigma); GFP (Clontech). The
Thoc5 and Uap56 antibodies have been described previ-
ously (13). A rabbit polyclonal antibody was raised against
GST-luzp4(N) (expressed from pGEX6P1-Luzp4(aa
119–313)) and used for western analysis (Figure 5 and
Supplementary Figure S8B). Cell lines used in functional
complementation experiments were built using the strategy
depicted in Supplementary Figure S6B and described
previously (10), resulting in the expression of Luzp4 (or
its mutant versions) with EmGFP fused to its C-terminus.
miRNAs hairpins also expressed from these constructs and
targeting Alyref and/or Uif were from (9). Growth curves
were performed as described previously (9). To determine
statistical differences in growth between the various cell
lines examined, we first log10-transformed the number
of cells obtained for each cell line from Day 4 (when the
curves start to scatter) for each independent experiment.
The slopes of the linear regressions applied to these values
were compiled and these growth rates were then compared
by a one-way ANOVA analysis followed by a Tukey test.
siRNA treatments and colony formation assays
For each RNAi condition, three wells of 6-well plates
with 50 000 cells/well were transfected twice with
40 nM of the indicated siRNAs and 12 l Interferin
(PolyPlus-transfection R©)/well (renewed at 48 h). Con-
trol siRNA, targeting dsRED sequence, and ALYREF
siRNA were 5′-CACCGUGAAGCUGAAGGUG-
3′ and 5′-GGAACUCUUUGCUGAAUUU-3′, re-
spectively (7). Uif knockdown was performed with
a pool of two siRNAs purchased from Dharma-
con: 5′-ACAUAAACAGUGUCGGAAA-3′, 5′-
GCAAAGAGAACUCGUCAAU-3′. Luzp4 knock-
down was performed with a pool of two siR-
NAs: 5′-GCCUUCAAGACAGCAAUCA-3′, 5′-
CAGAAGGAAAUCCGGACAA-3′. At 60–65 h post
transfection (seeding day), each well was phosphate
buffered saline (PBS) washed and treated with 100 l
trypsin. All three wells of each RNAi condition were then
inactivated and pooled with 2 ml of serum-containing
medium. Cell suspensions were homogenized, counted and
diluted to 200 cells/ml.
For each RNAi condition, a new 6-well plate was
seeded at 200 cells/well, therefore representing six
replicates/condition. Each well was adjusted to 2 ml
of culture medium and left to grow at 37◦C for 10 (293T
cells) to 14 days (MeWo cells). On the counting day, cells
were washed once with PBS and stained 5 min with 1
ml of crystal violet (0.5 % giemsa powder in methanol)
/ well. Each well was then washed twice with 1 ml of
deionized water and left to dry for at least 15 min. The
entire experiment was repeated five times independently
and only colonies containing at least 50 cells were counted.
One-way ANOVA analysis followed by a Tukey test was
performed to compare the effect of each siRNA-treatment
on MeWo and 293T cellular proliferation in Figure 6D and
Supplementary Figure S8B, respectively.
Luzp4–6His protein expression and purification
pET24b-Luzp4–6His was transformed into Rosetta2 cells.
Five litres of 37◦C pre-warmed terrific broth medium (50
g/ml Kanamycin) was inoculated from a 100 ml overnight
culture (terrific broth, 50 g/ml Kanamycin, 34 g/ml
Chloramphenicol) to give a starting OD600 of 0.05. The
cells were grown at 37◦C up to OD600 = 0.5. Production of
Luzp4–6His was then induced with 0.5 mM IPTG for three
and a half hours at 37◦C. Cells were harvested and lysed by
sonication on ice in binding buffer (50 mM Tris-HCl pH 8, 1
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1 mM PMSF, 1X SigmaFASTTM Protease Inhibitors). The
lysate was cleared by centrifugation at 30 000xg for 30 min
at 4◦C. The pellet of insoluble material was washed twice
with binding buffer and resuspended in 100 ml of denat-
uration buffer (50 mM Tris-HCl pH 8, 500 mM NaCl, 8
M Urea) for 20 min at room temperature. Denatured mate-
rial was first cleared by centrifugation and then incubated
with 5 ml of Cobalt beads (TALON R©) for 30 min. The col-
umn was then washed three times with 20 ml of wash buffer
(50 mM Tris-HCl pH 8, 1 M NaCl, 5 mM imidazole, 8 M
Urea). Luzp4–6His was eluted with 6 × 5 ml of elution
buffer (50 mM Tris-HCl pH 8, 1 M NaCl, 200 mM imidazol,
8 M Urea). Glycerol and ethylenediaminetetraacetic acid
(EDTA) were immediately added to the pooled fractions at
10% and 1 mM final, respectively. Finally, the purified pro-
tein was immediately dialysed twice against 5 l of dialysis
buffer (50 mM Tris-HCl pH 7.5, 0.5 M NaCl, 0.05% NP40,
50 mM L-Arginine, 50 mM L-Glutamate, 10% glycerol). In
total, ∼40 mg of soluble Luzp4–6His protein was obtained
and kept frozen at −80◦C as aliquots. GB1-Alyref-6His was
produced and purified as described previously (10).
GST-pulldown experiments and Co-IP
GST-pulldown experiments and Co-IP experiments were
carried out as described previously (10,13) using RB100
buffer for GST pulldowns (25 mM HEPES pH 7.5, 100 mM
KOAc, 10 mM MgCl2, 1 mM dithiothreitol, 0.05% Triton
X-100, 10% glycerol, 10 g/ml RNase A) and IP lysis buffer
for Co-IPs (50 mM HEPES pH 7.5, 100 mM NaCl, 1 mM
EDTA, 1 mM dithiothreitol, 0.5% Triton X-100 and 10%
glycerol + (10 g/ml RNase A) as indicated in figures). The
mRNP capture assays were carried out as described previ-
ously (13).
Mass spectrometry analysis
For mass spectrometry analysis, 20 × 15 cm dishes of the
Flp-InTM T-RExTM 293 FLAG-Luzp4 or control Flp-InTM
T-RExTM 293 FLAG stable cell lines were induced for 48
h with 1 g/ml of tetracycline and used for the IP with
anti-FLAG MS2-agarose beads (Sigma). Interacting part-
ners were eluted using 1 M Arginine-HCl (pH 3.5) and sub-
sequently brought to pH 7.5 using 1.5 M Tris-HCl pH 8.8.
In solution and in gel tryptic digestions were performed
as previously described (29,30). Tryptic digests were resus-
pended in 0.1% final concentration of Trifluoroacetic acid
(TFA). Five microlitres was used for LC-MS/MS analy-
sis. Peptides were separated using an Ultimate 3000 RSLC
nano liquid chromatography system (ThermoFisher, UK),
using a 150 mm × 75 m I.D. PepMap reversed phase
column (ThermoFisher, UK). Linear gradient elution was
performed from 95% buffer A (0.1% formic acid) to 40%
buffer B (0.1% formic acid, 95% acetonitrile) at a flow rate
of 300 nl/min in 60 min. MS/MS analysis was performed
using a maXis UHR TOF mass spectrometer (Bruker Dal-
tonics) using an automated acquisition approach. MS and
MS/MS scans (m/z 50–2000) were acquired in positive
ion mode. Lock mass calibration was performed using HP
1221.990364. Line spectra data were then processed into
peak list by Data Analysis (Bruker Daltonics) using the fol-
lowing settings. The sum peak finder algorithm was used
for peak detection using a signal-to-noise ratio of 10, a rela-
tive to base peak intensity of 0.1% and an absolute intensity
threshold of 100. Spectra were deconvoluted and the peak
lists exported as Mascot Generic Files (MGF) and searched
using Mascot 2.2 server (Matrix Science) The Swiss-Prot
database (Swiss-Prot Release 10.5, 20 April 2010, 516 604
sequences) was searched using the following parameters
(analysis peptide tolerance = ± 0.01 Da, MS/MS tolerance
= ±0.01 Da and peptide charge 2+ and 3+). Search param-
eters were as follows: enzyme; trypsin; variable modifica-
tions: deamidation (NQ), oxidation (M); maximum missed
cleavages = 1. A peptide ion score of ≤ 10 as a cut-off as cal-
culated by Mascot was also used to filter. The false discov-
ery rates were determined using the Mascot decoy database
option and were ≤1%. Protein identifications were based
on a minimum of two unique peptides. Mass spectrom-
etry search results generated by Mascot (*.dat) were im-
ported into ProHits Lite-VM 2.0.3 (http://prohitsms.com/)
run via Virtual Box 4.3.6 (https://www.virtualbox.org/) on
OSX 10.8.5. A comparison was then performed in Prohits
(31) between the lists of proteins for Luzp4 IP and Control
IP. Filters used were: Artefacts proteins, Keratin, Albumin
and Cytoskeleton. Proteins that passed the filtering and the
analysis are presented in Supplementary Table S1. The pro-
teins present in Control IP were then removed from the list
of Luzp4 interacting partners. The new filtered list of pro-
teins was used to generate the cytoscape diagram (32) de-
picted in Figure 2E.
MS2 mRNA export assays
Assays were carried out as described previously (9).
Nxf1 remodelling assays and UV-crosslinking experiments
The Nxf1 remodelling assay and UV cross-linking
experiments were carried out as described previ-
ously (10). The ssDNA used in some assays was 5′-
CTCTAGATCAACCACTTTGT-3′. The integrated pixel
densities function of the software ImageJ (33) was used to
measure and normalize the pixel densities of the phospho-
rimage signals to the pixel densities of the corresponding
Coomassie-stained gel signals. The radiolabelled RNA-
crosslinking fold increase was calculated as the increase
of crosslinking observed for a given condition relative to
the crosslinking observed for the relevant bovine serum
albumin (BSA)-containing reactions (RNA or ssDNA).
Fluorescence in situ hybridisation and immunostaining
Fluorescence in situ hybridisation (FISH) and immunos-
taining were carried out as described previously (13). Using
the ImageJ software (NIH), the nuclear rim of cells in the
poly(A)+ panels of Figure 4A was determined by creating
outline-masks from the corresponding DAPI images which
were then applied onto the poly(A)+ signal images. The re-
sulting images were used to perform fluorescence intensity
scans with a line width of 5 pixels and a length of 56 pixels.
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Figure 1. Interaction of Luzp4 with mRNA export factors. (A) Schematic of Luzp4 putative domains organisation. The UBM previously identified in
Alyref and Uif is aligned with the homologous sequence identified in Luzp4. Residues in bold show strict identity to Alyref sequence. Black dots show
biochemically conserved positions. Arginine-Serine (RS) dipeptides are indicated as vertical grey bars. The alternative names used for Luzp4 are also
shown. (B) GST pulldown assays with the indicated proteins. (C) Co-IP assays using the indicated expression vectors. Western blots were probed with the
indicated antibodies. (D) GST-pulldown analysis of 35S labelled Luzp4 truncations as indicated with either GST-Nxf1:p15 (right panel) or GST-Uap56
(lower panel). The 35S labelled protein inputs are shown in the left panel. In each case the panel shown is a phosphoimage. Corresponding Coomassie-
stained gels are presented in Supplementary Figure S2B. (E) Schematic of the truncation constructs used to map binding sites for Nxf1 and Uap56 and
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Supplementary Figure S9B, DAPI images of wide-field pic-
tures (20x Leica objective) were thresholded, binary trans-
formed, and cells were automatically counted using the Im-
ageJ software. Pictures containing at least 200 cells (Fig-
ure 4B) or at least 60 cells (Supplementary Figure S9B)
were collected and their corresponding poly(A)+ signal im-
ages were thresholded and used to only count cells dis-
playing saturated poly(A)+-RNAs nuclear accumulation. A
one-way ANOVA analysis followed by a Fisher’s LSD test
was used to determine which cell lines were prone to dis-
play a poly(A)+-RNA export block compared to the Con-
trol RNAi cell line.
Luzp4 expression screening in tumour samples
Origene TissueScan Cancer 96-well plates that contained
pre-normalized cDNA samples isolated from 18 different
body tissues were used according to the manufacturer’s in-
structions. Supplementary Table S2 provides patient details
and tumour grades. The PCR primers used were as follows:
Alyref forward 5′-GCCTGCACAGAGCGTAAACA-3′,
Alyref reverse 5′-CTCGCATTATTATAGGCGTCCAG-
3′, Luzp4 forward 5′-CGCCTTCAAGACAGCAATCA-
3′, Luzp4 reverse 5′-CACTGCACTTCTCCTGCTCAA-
3′, Uif forward 5′-AGCAGTGCAATGCCCAGTAA-3′
and Uif reverse 5′-ACCGCTCATTCAACGTCATC-
3′. U1 forward 5′-ACCTGGCAGGGGAGA-3′ and
U1 reverse 5′-GGGGAAAGCGCGAAC-3′ Expression
values plotted in Supplementary Figure S7 are shown as
2−CT using U1 snRNA as the normalizer.
RESULTS
Luzp4 associates with Nxf1 and TREX subunits
A BLAST search with the UBM from the N-terminal do-
main of Alyref (9) identified Luzp4 (also called HOM-TES-
85 or CT-8), a CTA with unknown function. Luzp4 is re-
ported to reside within nuclear speckles, a site enriched in
factors involved in pre-mRNA processing and mRNA ex-
port (34). Luzp4 orthologues were clearly identifiable in
other animals. However, analysis of the X-chromosome in
mice revealed a gene expansion at the locus where Luzp4
lies in other species and one Luzp4 paralogue in mice is
known as ovary and testis transcribed (Supplementary Fig-
ure S1A). Luzp4 harbours a single UBM in its N-terminal
domain, a central domain rich in arginines, serine dipep-
tides and histidines (RS-H) and a C-terminal leucine zip-
per motif (Figure 1A and Supplementary Figure S1B). We
found that following an internal deletion of amino acids (aa)
156–236, which encompasses the RS-H region, GFP-Luzp4
localized to the cytoplasm, whereas wild-type Luzp4 was
nuclear, suggesting the RS-H region contains the nuclear lo-
calisation sequence of Luzp4 (Supplementary Figure S1C).
Interestingly, deletion of the UBM region (aa 22–40) altered
the nuclear distribution of GFP-Luzp4, leading to the for-
mation of fewer and larger GFP-Luzp4 foci.
To establish whether Luzp4 directly associated with
Uap56 or Nxf1, we used GST pulldown assays with pu-
rified Luzp4 protein produced in E. coli (Figure 1B). We
found that both GST-Uap56 and GST-Nxf1 bound Luzp4
whereas the GST control did not. We also observed the
Co-IP of Luzp4 with FLAG-Nxf1-myc and FLAG-Uap56-
myc from human cells (Figure 1C). This interaction was not
affected by RNase treatment, indicating it was not RNA-
dependent, whereas Co-IP of FLAG-Sfrs1 with Cbp80 was
RNA dependent (Figure 1C, lanes 9, 10) as reported pre-
viously (13). Since the expression of Luzp4 is restricted to
testis in normal human tissues (34) where Nxf2 is expressed,
we used Co-IP analysis to establish that Luzp4 also binds
Nxf2 (Supplementary Figure S2A). In order to map the re-
gions of Luzp4 responsible for interaction with Uap56 and
Nxf1, a deletion series was designed and made on the basis
of the protein sequence annotation in Figure 1 and Supple-
mentary Figure S1, the secondary structure prediction in
Figure 1, and constraints imposed by repetitive DNA mo-
tifs within Luzp4 cDNA sequence restricting primers de-
sign. These deletion mutants were used in GST-pulldown
experiments (Figure 1D, Supplementary Figure S2B). Nxf1
associated strongly with the C-terminal domain of Luzp4
and weakly with the N-terminus, whereas Uap56 associ-
ated with aa 1–119 strongly, which encompasses the UBM
but only interacted weakly with C-terminal fragments of
Luzp4. We conclude that Luzp4 forms direct interactions
with both Uap56 and Nxf1 in vivo and thus has similarities
with the mRNA export adaptors Alyref and Uif.
Luzp4 binds RNA, associates with TREX subunits and func-
tions with Nxf1 in vivo
Because of its cellular localisation and its ability to bind
Nxf1 and Uap56, we thought that Luzp4 could be a new
RNA-binding protein, despite a lack of obvious RNA-
binding features in its protein sequence. To investigate
whether Luzp4 binds RNA, we used UV-crosslinking as-
says and compared its ability to bind both single-stranded
DNA and RNA with that for Alyref. Luzp4 crosslinked
strongly with single-stranded RNA at low KCl concentra-
tions and this crosslinking was dependent on UV irradi-
ation (Figure 2A, Supplementary Figure S3A). However,
the crosslinking was inhibited by higher KCl concentrations
suggesting an ionic interaction between Luzp4 and RNA.
Alyref also showed inhibition of RNA binding at higher
KCl concentrations suggesting an ionic interaction which
is consistent with the earlier observation that arginines are
involved in the Alyref:RNA interaction (35). Alyref showed
very weak binding to single-stranded DNA, whereas Luzp4
showed stronger binding which was also sensitive to increas-
ing KCl. However the single-stranded DNA binding activ-
ity of Luzp4 is only 28% of the RNA binding activity, in-
dicating Luzp4 has clear preference for RNA over single-
stranded DNA binding in this assay. We mapped the do-
main responsible for interaction with RNA using trunca-
tions of Luzp4 (Figure 2B and C) and found the major
RNA binding activity resided between aa 119–313 with a
weaker RNA binding activity between aa 1–119. We con-
firmed that GFP-Luzp4 associates with the mRNP in vivo
using an mRNP capture assay (12) (Figure 2D, Supplemen-
tary Figure S3B). We also observed that loss of the do-
mains responsible for either Uap56 or Nxf1 interactions
(aa1–119 or 241–313, respectively) prevented GFP-Luzp4
from associating with the mRNP. Deletion of the Uap56
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Figure 2. Luzp4 is an RNA binding protein that associates with TREX subunits. (A) UV-crosslinking assays using recombinant Alyref, Luzp4 or BSA
control and 32P-labelled single-stranded RNA or DNA oligonucleotides. Lanes 2, 4, 7, 10 had 100 mM KCl, lanes 8, 11 had 300 mM KCl and lanes 3,
5, 9, 12 had 500 mM KCl in the reactions. The upper panel shows the phosphoimage of the same gel which is Coomassie stained in the lower panel. The
quantification shows the increase of crosslinking relative to the relevant BSA-containing reaction (ssDNA or ssRNA). Results where UV crosslinking
was omitted were exposed and acquired at the same time and are presented in Supplementary Figure S3A. (B) UV crosslinking of 32P-labelled RNA
oligonucleotide with the indicated purified truncations of Luzp4 in 100 mM NaCl. The upper panels show the phosphoimage of the Coomassie-stained
gels shown in the lower panels. (C) Schematic of the Luzp4 truncations used to map the RNA binding activity and summary of the RNA binding activity
for truncations measured using UV crosslinking. nd: not determined because the constructs are insoluble and precipitated repeatedly during refolding step
following purification. (D) Luzp4 binds poly(A)+-RNAs in vivo. The indicated GFP fusions of Luzp4 were analysed for binding to poly(A)+-RNAs in vivo
using UV crosslinking. Proteins were visualized by western blot with anti-GFP antibody. Results where UV crosslinking was omitted were exposed and
acquired at the same time and are presented in Supplementary Figure S3B. (E) Summary of the interacting proteins identified using mass spectrometry
following IP of FLAG-Luzp4 stably expressed in Flp-InTM T-RExTM 293 cells (see Materials and Methods). (F) Validation of the mass spectrometry
samples. Proteins co-immunoprecipitating with FLAG or FLAG-Luzp4 were detected using western blotting with antibodies to the indicated proteins and
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GFP-Luzp4 within the nucleus from a punctate to a more
diffuse localisation (Supplementary Figure S3C).
To further characterize Luzp4, we immunoprecipitated
FLAG-Luzp4 stably expressed from a Flp-InTM T-RExTM
293 cell line and screened for binding partners by mass spec-
trometry. This analysis identified numerous TREX com-
ponents, together with other proteins involved in RNA
metabolism including components of the exon junction
complex and several SR proteins (Figure 2E, Supplemen-
tary Table S1). Interestingly, Ars2/Srrt was present in the
Luzp4 IP and has previously been shown to Co-IP with
TREX (3). Some of these interacting proteins were vali-
dated further by western blot performed on the samples
used for the mass spectrometry analysis (Figure 2F). Over-
all, the Luzp4 interactome obtained here is consistent with
its localisation in the nuclear speckles where splicing occurs
(34,36) and is also consistent with a role in gene expression
and mRNA processing. These results further suggest that
Luzp4 assembles with TREX in vivo, like Alyref and Uif
(9).
mRNA export adaptors such as Alyref and Uif preferen-
tially bind to aa 1–198 of Nxf1 whereas co-adaptor proteins
such as Chtop or Thoc5 mainly bind Nxf1 via the central
NTF2L domain. Pulldown assays established that Luzp4
associates with aa 1–198 of Nxf1 (Figure 3A). On bind-
ing aa 1–198 of Nxf1, adaptors such as Alyref hand their
bound mRNA over to Nxf1. Alyref binding also stimulates
partial exposure of the Nxf1 RNA binding domain which
leads to enhanced RNA binding by Nxf1 (12,13). We as-
sessed the RNA binding activity of a GST-Nxf1-p15:Luzp4
complex using UV cross-linking (Figure 3B) and found that
on binding Luzp4, the RNA crosslinking activity of Nxf1
increased (Figure 3B, compare lanes 6 and 8). Furthermore,
when Luzp4 is complexed with Nxf1, it shows significantly
reduced RNA cross-linking activity (Figure 3B, compare
lanes 2 and 8). We conclude that upon binding to Nxf1,
Luzp4, in common with other mRNA export adaptors, has
the ability to enhance the RNA binding activity of Nxf1
while simultaneously handing the RNA over to it.
To explore the functional relationship between Luzp4
and Nxf1 in vivo, we utilized a tethered mRNA export as-
say in which an mRNA export factor can overcome nu-
clear retention of an inefficiently spliced pre-mRNA lead-
ing to expression of luciferase retained within an intron
(Figure 3C, Supplementary Figure S4) (3,14). As reported
previously (12), MS2-Nxf1 stimulated luciferase expres-
sion strongly (∼75-fold), whereas MS2-Alyref stimulated
expression by 5.8-fold, reflecting its requirement to subse-
quently recruit Nxf1 prior to mRNA export (Figure 3C).
MS2-Luzp4 showed a modest but reproducible ∼2-fold in-
crease in reporter expression. Overexpression of untethered
FLAG-Nxf1 also led to a ∼2-fold increase in luciferase ex-
pression and this effect has been reported previously with
a similar reporter (37). Strikingly, when either Luzp4 or
Alyref were tethered to the reporter mRNA via MS2, and
FLAG-Nxf1 was simultaneously overexpressed, there was
a large increase in luciferase expression (10.2- and 22.2-
fold activation, respectively) indicating that Luzp4 or Alyref
can work synergistically with Nxf1 in this assay. The strong
synergistic effect observed on overexpression of Nxf1 indi-
cates that endogenous Nxf1 levels may be limiting in this
assay. This could in part be due to inefficient recruitment of
Nxf1 to a tethered export adaptor which may fail to asso-
ciate with additional TREX subunits such as Thoc1, Chtop
and Thoc5 which also mediate Nxf1 interactions (13,38).
Increasing the concentration of Nxf1 may compensate for
the loss of interactions with additional TREX subunits with
the isolated tethered export adaptor, leading to enhanced
mRNA export.
We investigated the impact of Luzp4 expression on Nxf1
localisation in vivo (Figure 3D). Transiently transfected
FLAG-Nxf1 showed a diffuse nuclear staining and staining
at the nuclear rim as reported previously (39) whereas GFP-
Luzp4 showed a punctate staining pattern, as observed pre-
viously (34). When GFP-Luzp4 and Flag-Nxf1 were co-
expressed, we observed loss of the nuclear rim staining for
Nxf1. These data are consistent with the earlier observation
that overexpression of Srsf1, which also binds and func-
tions with Nxf1, can prevent its association with the nu-
clear rim (40). Moreover, whilst inhibition of transcription
by actinomycin D had no effect on FLAG-Nxf1 localisa-
tion, it resulted in a diffuse nuclear distribution for GFP-
Luzp4. Interestingly, this change in GFP-Luzp4 localisa-
tion upon transcription inhibition was concomitant with a
persistence of FLAG-Nxf1 staining at the nuclear rim of
cells co-expressing both proteins. We also examined GFP-
Luzp4 and Nxf1 localisation in cells at different stages of
the cell cycle and found that GFP-Luzp4 relocalizes to the
cytoplasm in newly divided cells, whereas Nxf1 remains nu-
clear and retains nuclear rim staining (Supplementary Fig-
ure S5A). The leucine zipper domain of Luzp4 is involved
in this phenomenon since the mutant Luzp4C(aa 1–240)
is almost exclusively nuclear in newly divided cells (Sup-
plementary Figure S5B). Together, these data indicate that
there is a functional relationship between Nxf1 and Luzp4
in vivo and Luzp4 can alter the steady-state localisation of
Nxf1 in a transcription-dependent manner.
Luzp4 complements loss of Alyref in vivo
We noted that Alyref RNAi did not lead to up-regulation
of endogenous Luzp4 expression in 293 cells (Supplemen-
tary Figure S6A). This provided an opportunity to artifi-
cially express Luzp4 and test whether it would complement
the mRNA export and growth defects observed following
Alyref RNAi in a 293 cell. To do this, we generated stable
Flp-InTM T-RExTM 293 cell lines in which Luzp4 was ex-
pressed as a GFP fusion in a transcript with miRNAs in its
3′ UTR targeting either Alyref or Alyref+Uif (Supplemen-
tary Figure S6B). We analysed these cell lines for mRNA
export defects using oligo(dT) FISH (Figure 4A and B).
Alyref RNAi led to an mRNA export block as reported
previously with clear nuclear accumulation of poly(A)+-
RNA (9). However, Luzp4 expression complemented this
mRNA export defect, indicating that Luzp4 can function
as an mRNA export factor in place of Alyref. In contrast, a
GFP fusion of Luzp4 missing aa 1–118 (Luzp4(N)-GFP)
which does not bind Uap56 (Figure 1D and E), or a GFP
fusion of Luzp4 aa 1–240 (Luzp4(C)-GFP), which binds
Nxf1 and RNA poorly, did not complement the mRNA ex-
port defect triggered by Alyref RNAi (Figure 4A and B).
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Figure 3. Luzp4 is an mRNA export adaptor. (A) The purified GB1-tagged Nxf1 proteins used in pulldown assays are shown (left panel). IgG-Sepharose
pulldown assays using 35S-Luzp4 and the indicated GB1-tagged Nxf1 proteins (right panels). The upper panel is the phosphoimage of the same gel which is
Coomassie stained in the lower panel. (B) Nxf1 remodelling assays. Luzp4 pre-incubated with a 32P-labelled RNA oligonucleotide was incubated with im-
mobilized GST or GST-Nxf1:p15. The indicated complexes were then purified by GST-pulldown, eluted, UV-crosslinked and analysed by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis. The upper panel is the phosphoimage of the same gel shown Coomassie stained in the lower panel. Input was
1%. (C) Tethered mRNA export assays (also see Supplementary Figure S4A). The indicated MS2 fusion protein expression vectors were co-transfected
with the MS2 reporter pLUCSALRRE6MS2, normally retained in the nucleus, together with a -galactosidase expression vector. Luciferase activities were
measured from the MS2 reporter and normalized for transfection efficiency with the -galactosidase activities. The graph shows fold activation relative to
the levels seen with MS2-GFP and values represent averages from experiments carried out in triplicate on five separate occasions. (D) Immunofluorescence
images of HeLa cells transfected with the indicated expression vectors. FLAG-Nxf1 was detected using FLAG antibody. When indicated, cells were treated
with 5 g/ml of actinomycin D for 3 h. Certain regions of images indicated by a white box are shown at higher magnification in the bottom left of a panel
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Figure 4. Luzp4 can complement knockdown of other mRNA export adaptors. (A) The indicated stable inducible RNAi cell lines were analysed for
GFP fusion expression (left panels), for poly (A)+-RNA using FISH analysis with oligo-(dT)50 (central panels), and an overlay of DAPI stained cells and
the poly(A)+ signal is shown in the right panels. RNAi-mediated knockdowns were induced for 96 h. Fluorescence intensity scanning of indicated cells
(white bars) are shown on the right. The y-axis of the graphs represents the pixel intensity (Px Int.) and the x-axis the distance in pixels (Dist. (px)). All
equivalent panels are shown at the same exposure. (B) Quantification for the results presented in panel A. Three images (with at least 200 cells each) per
condition were used to count the proportion of cells displaying a nuclear accumulation of poly(A)+ RNAs. Mean values ± standard deviation are shown.
PCtrl RNAi versus ALYREF RNAi-LG = 0.5262. (C) Growth of stable cell lines following induction of the indicated miRNAs and complementing cDNAs with
tetracycline. Mean values ± standard deviation from five independent experiments are shown. The statistical differences in growth rates are shown on the
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Figure 5. Luzp4 rescues the mRNA export pathway impaired in ALYREF
RNAi cells. Western blot analysis of stable cell lines following induction of
the indicated miRNAs and complementing cDNAs at the indicated time
points. The antibodies used to detect the proteins are indicated on the
right-hand side of each panel. Tetracycline is used to induce expression of
the miRNA/complementing cDNA. Supplementary Figure S6B provides
a schematic of the complementation system. LG = Luzp4-GFP.
extreme mRNA export block with robust nuclear accumu-
lation of large areas of poly(A)+ material in the majority
of cells ((9) and Figure 4A and B). This mRNA export
block was partially complemented by expression of GFP-
Luzp4, with fewer cells showing strong nuclear accumula-
tion of poly(A)+-RNA. We also examined the expression
of the GFP fusions in the stable cell lines (Figure 4A, left
panels) and found that the levels of GFP protein were re-
duced following Alyref RNAi and further reduced follow-
ing Alyref + Uif RNAi. GFP-Luzp4 also showed reduced
expression following Alyref+Uif RNAi compared with just
Alyref RNAi. This probably arises from reduced GFP or
GFP-Luzp4 mRNA export in cell lines following Alyref
and Uif RNAi. Despite this, the lower levels of GFP-Luzp4
following Alyref + Uif RNAi were still able to partially
complement mRNA export (Figure 4A and B). We further
examined the ability of Luzp4 to complement the growth
defect observed following Alyref and Uif RNAi using the
stable cell lines generated for the FISH analysis. Whereas
Alyref and Alyref+Uif combined RNAi cell lines showed a
clear growth defect (Figure 4C), both cell lines showed sig-
nificantly better growth when they expressed GFP-Luzp4.
However, the cell growth was not completely restored to
normal levels, particularly when both Alyref and Uif were
knocked down by RNAi.
When mRNA export is blocked, cells respond by up-
regulating a variety of mRNA export factors (9,11). We
therefore also assessed what happens in cells following
Alyref or Alyref+Uif RNAi and the impact that expres-
sion of GFP-Luzp4 had in such cells using the complemen-
tation cell lines described above. Following Alyref RNAi
we saw a clear up-regulation of Uif, Nxf1 and Uap56 pro-
tein levels (Figure 5, lanes 18–20). In contrast, an mRNP
binding factor not directly associated with mRNA export,
Hnrnpa1, was not affected (Figure 5, lanes 18–20). When
GFP-Luzp4 was co-expressed in the Alyref RNAi cell line,
the up-regulation of Nxf1 and Uap56 was suppressed, par-
ticularly at later time points of expression (Figure 5, com-
pare lanes 20 and 24). However, Uif levels remained raised
following Alyref RNAi and were not suppressed by GFP-
Luzp4 expression. We also examined the ability of comple-
menting cell lines expressing non-functional mutant forms
of Luzp4 to suppress the up-regulation of export factors fol-
lowing Alyref RNAi and found that neither mutant forms
of Luzp4 could suppress this response (Figure 5, lanes 26–
28, lanes 30–32). Finally, we examined the ability of GFP-
Luzp4 expression to suppress up-regulation of export fac-
tors following Alyref+Uif RNAi and found that it could not
(Figure 5, lanes 34–36). Together, these results indicate that
Luzp4 functions as an mRNA export factor in human cells
that is able to restore mRNA export function in cells com-
promised by loss of mRNA export adaptors.
Luzp4 is preferentially expressed in melanomas
Since Luzp4 was originally described as a CTA we exam-
ined Luzp4, Alyref and Uif expression in tumour biopsies
from 402 different patients, representing multiple different
clinical stages of tumours from a wide range of tissues (Fig-
ure 6A, Supplementary Figure S7 and Supplementary Ta-
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were low compared with Alyref and Uif, although we ob-
served at least one tumour biopsy that showed increased
Luzp4 expression within most tissue types. The striking ex-
ception was malignant melanoma where Luzp4 expression
was very high for many patients. This is consistent with the
earlier qualitative observation of Luzp4 expression in multi-
ple melanoma samples (34). These data suggest that Luzp4
expression is preferentially activated in melanoma.
To identify cells suitable for further studies on Luzp4, we
screened various cancer cell lines for expression of Luzp4
and found that the melanoma cell line MeWo had read-
ily detectable expression (Supplementary Figure S8A). We
confirmed the expression of Luzp4 in MeWo cells using
qRT-PCR and found that the levels were significantly lower
than those for both Uif and Alyref and found no detectable
expression of Luzp4 in 293T cells (Figure 6B). We also
raised two separate antibodies to Luzp4 and screened for
Luzp4 protein (Supplementary Figure S8B) in Mewo cells.
Whilst the antibody was able to detect Luzp4 when tran-
siently overexpressed we were unable to unambiguously de-
tect the endogenous protein with our antibodies, suggesting
that it is present at low levels as indicated by the qRT-PCR
analysis.
We investigated whether Luzp4 RNAi led to a detectable
block in mRNA export in Mewo cells using oligo d(T) FISH
(Supplementary Figure S9) and whilst we could see a clear
block of export following Alyref RNAi, no such block was
seen following Luzp4 RNAi. Therefore Luzp4 may be re-
sponsible for the export of a restricted set of mRNAs. We
further analysed the effects of Luzp4, Alyref and Uif RNAi
on the growth of Mewo cells using a colony formation as-
say (Figure 6D). Alyref RNAi led to a significant growth
defect in Mewo cells, whereas Uif RNAi did not, suggesting
it was not essential for cellular proliferation, as previously
observed in 293T cells (9). Luzp4 RNAi led to a significant
drop in the number of Mewo cell colonies formed. Impor-
tantly, Luzp4 siRNAs did not affect cellular proliferation
of 293T cells (Supplementary Figure S8C), where Luzp4
is not expressed, indicating they do not have off-target ef-
fects which affect general cellular growth. We conclude that
Luzp4 is required for the growth of Mewo cells.
DISCUSSION
Luzp4 was first defined as a CTA 13 years ago but its molec-
ular function has remained unknown until now. We have
shown that Luzp4 is a new RNA binding protein and we
have mapped two regions of the protein involved in this ac-
tivity. One is an arginine-rich region located after the UBM,
as is the case with Alyref. The second region involved in
RNA binding maps to the leucine zipper motif and inter-
estingly a helical wheel projection of the amino acids within
the leucine zipper reveals a positively charged surface which
may be required for RNA interactions (34). We have further
demonstrated that Luzp4 functions as an mRNA export
factor, capable of complementing knockdown of Alyref
and partially complementing a double Alyref/Uif knock-
down in 293 cells. Luzp4 has a UBM that allows associa-
tion with Uap56. Given that Uap56 drives TREX assem-
bly (3,10), this interaction probably ensures the incorpo-
ration of Luzp4 in the TREX complex. Consistent with
this, the UBM is required for proper nuclear distribution
of Luzp4 and we observed Co-IP of Luzp4 with TREX
subunits. A common property of mRNA export adaptors
such as Alyref, Srsf3 and Srsf7 is their ability to bind the N-
terminal region of Nxf1 and enhance its RNA binding ac-
tivity (12). This involves release of the Nxf1 RNA binding
domain from its interaction with the NTF2L domain (13).
Here, we observe that Luzp4 also has the ability to enhance
the RNA binding activity of Nxf1 through an interaction
with the Nxf1 N-terminal region. Thus Luzp4 can be clas-
sified as a new mRNA export adaptor.
Luzp4 was originally reported to be expressed in human
testis (34) and a more extensive survey of its tissue specific
expression by the Human Protein Atlas project (41) (http:
//www.proteinatlas.org/ENSG00000102021-LUZP4/tissue)
confirms this restricted expression pattern. Interestingly,
Luzp4 is able to interact with Nxf2 which may be the
major mRNA export receptor in this tissue. Whilst
testes express Luzp4, they also express Alyref (http:
//www.proteinatlas.org/ENSG00000183684/tissue/testis)
and thus it is unlikely that Luzp4 acts as the sole mRNA
export adaptor in this tissue. Why the testis has evolved
distinct mRNA export factors remains unclear, though it
may be related to the meiotic gene expression programme
in this tissue.
The ability of Luzp4 to complement the export defect
seen following Alyref RNAi implies that it has the abil-
ity to associate with a wide variety of mRNAs in a 293
cell. This indicates there is functional redundancy between
Alyref and Luzp4 as reported previously for Uif and Alyref
(9). Indeed Alyref is clearly playing a major role in mRNA
export in Mewo cells, since its knockdown leads to a sig-
nificant mRNA export block and prevents cellular prolif-
eration. Interestingly in a number of high grade tumours,
Alyref expression levels are reported to be diminished (24).
Therefore, given the potential functional redundancy be-
tween Alyref and Luzp4, it seems plausible that in certain
tumours, Luzp4 may function to promote the export of
mRNAs which would normally utilize Alyref. Since Luzp4
RNAi in Mewo cells does not lead to a strong accumulation
of mRNA when assayed by FISH it is possible that the ex-
port of a restricted set of mRNAs is dependent on Luzp4 in
these cells.
Luzp4 was originally discovered using the SEREX tech-
nique, whereby circulating antibodies from a seminoma pa-
tient were used for expression screening of testis cDNA
libraries. It was further shown to be expressed in a wide
variety of cancers including melanoma, seminoma, ovar-
ian, lung and glioma and its expression could be activated
in normal cells by addition of the DNA methylation in-
hibitor, 5-aza-2′-deoxycytidine (34). Here, we have extended
that analysis of the Luzp4 expression profile in cancer cells
and found it is expressed in a wide variety of cancer types,
but particularly high levels of expression are observed in
melanoma cells. Recent work identified Luzp4 as commonly
up-regulated in multiple myeloma (MM) cell lines and the
bone marrow of MM patients, a cell-type absent from our
screen of tumours (42). Furthermore this study showed
that Luzp4 knockdown prevented colony formation for an
MM cell line and sensitized the cell line to chemothera-
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Figure 6. Luzp4 is expressed in cancer cells and involved in MeWo cell growth. (A) Summary of the qRT-PCR analysis of Luzp4, Uif and Alyref expression
in RNA samples derived from 402 different patients, representing multiple different clinical stages of tumours from many tissues. The full data set for each
tissue is shown in Supplementary Figure S7. Genes were defined as expressed when 2−CT >0.04. (B) qRT-PCR analysis of expression Alyref, Uif and
Luzp4 in MeWo and 293T cells. Values for LUZP4 levels in 293T and MeWo were 0.00055 and 0.06433, respectively. The results represent the average
of three independent experiments. The error bars represent the standard deviation. (C) qRT-PCR analysis to confirm efficient knockdown of ALYREF,
LUZP4 and UIF mRNA in MeWo cells using siRNAs. The values shown are normalized to U1 snRNA abundance. The error bars represent the standard
deviation from three independent experiments. (D) Colony formation assay for MeWo cells following knockdown of the indicated mRNAs using siRNAs.
The values shown for all graphs represent the average of five independent experiments, each containing six replicates per condition and the error bars
represent the standard deviation. **P < 0.01, ***P < 0.001, ****P < 0.0001.
data are consistent with our observation that the Mewo
melanoma cell line also requires Luzp4 for efficient colony
formation. Therefore, at least two types of cancer cells share
the requirement for Luzp4 for efficient growth and, given
its restricted expression profile in non-disease states, it may
be an appropriate target for development of drugs or im-
munotherapies to treat MM or melanoma.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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